Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. (Q38323786)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Angela Martino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Russell G A Jones

series ordinal

1

1 reference

2 September 2017

Angela Martino

series ordinal

2

1 reference

2 September 2017

publication date

20 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Biotechnology

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

506-520

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

Clinical use of anti-TNF therapy and increased risk of infections

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

A pilot trial using topical regular crystalline insulin vs. aqueous zinc solution for uncomplicated cutaneous wound healing: Impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Antibodies: an alternative for antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Slow and fast dietary proteins differently modulate postprandial protein accretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Kinetics of whole serum and prepurified IgG digestion by pepsin for F(ab')2 manufacture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Influence of format on in vitro penetration of antibody fragments through porcine cornea

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Passive antibody therapies: progress and continuing challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Passive antibody administration (immediate immunity) as a specific defense against biological weapons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Passive antibody therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Therapeutic antibodies: successes, limitations and hopes for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Therapeutic antibodies for autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

21 January 2018

Burn wound infections

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Role of the proximal and distal stomach in mixed solid and liquid meal emptying

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Breakthrough of the year 2013. Cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Antibody-based immunotherapy of cryptosporidiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Induction of immunological tolerance by oral anti-CD3

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Variability of gastrointestinal transit in healthy women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Single-domain antibody fragments with high conformational stability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Antibodies as specific chaperones.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Progress in intra-articular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Intradermal anti-loxosceles Fab fragments attenuate dermonecrotic arachnidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Systemic and topical immunoglobulin treatment in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Properties, production, and applications of camelid single-domain antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Enhanced pepsin digestion: a novel process for purifying antibody F(ab')(2) fragments in high yield from serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

The effects of specific antibody fragments on the 'irreversible' neurotoxicity induced by Brown snake (Pseudonaja) venom

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: A phase I feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Egg yolk antibodies for passive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Microencapsulation for the gastric passage and controlled intestinal release of immunoglobulin Y.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Treatment of inflammatory bowel disease: a review of medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Involvement of spectrin in membrane fusion: induction of fusion in human erythrocyte ghosts by proteolytic enzymes and its inhibition by antispectrin antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Psoriasis treatment: traditional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Effects of gender, age, and body mass index on gastrointestinal transit times

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Intratumoral immunization: a new paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

The growth and potential of human antiviral monoclonal antibody therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Oral tolerance induction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Antibody production: polyclonal-derived biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Cyclodextrin-based hydrogels toward improved wound dressings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Effect of luminal growth factor preservation on intestinal growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Surgical irrigation with pooled human immunoglobulin G to reduce post-operative spinal implant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

The hydrolysis of rabbit y-globulin and antibodies with crystalline papain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Antibody-based therapeutics to watch in 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Marketed therapeutic antibodies compendium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

The expanding role of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Emerging treatments for complex perianal fistula in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

High-level expression of Camelid nanobodies in Nicotiana benthamiana

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Eudragit: a technology evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Penetration of engineered antibody fragments into the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Passive immunity against human pathogens using bovine antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Combating multidrug-resistant Gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

A protocol for ‘enhanced pepsin digestion’: a step by step method for obtaining pure antibody fragments in high yield from serum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

Facile F(ab′)2 Manufacturing: Strategies for the Production of Snake Antivenoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07388551.2014.992388

10.3109/07388551.2014.992388

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json

release_2eqrebmvhrgcbmpa3lif7uytpm

28 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2eqrebmvhrgcbmpa3lif7uytpm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25600465%20AND%20SRC:MED&resulttype=core&format=json